Fluorouracil, Doxorubicin, and Mitomycin (FAM) Regimen for Gastrointestinal Cancers-Reference-Cited by-同舟云学术

Fluorouracil, Doxorubicin, and Mitomycin (FAM) Regimen for Gastrointestinal Cancers

Published:2005-11 Issue:11 Volume:40 Page:964-970
ISSN:0018-5787
Container-title:Hospital Pharmacy
language:en
Short-container-title:Hosp Pharm

Author:

Adejuwon Adesola F.¹,Solimando Dominic A.²,Waddell J. Aubrey³

Affiliation:

1. School of Business, Howard University, Washington, DC.

2. Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203

3. University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 East Lamar Alexander Parkway, Maryville, TN 37804

Abstract

The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Pharmacology,Pharmacy

Link

http://journals.sagepub.com/doi/pdf/10.1177/001857870504001105

Reference28 articles.

1. 5-fluorouracil, adriamycin, and mitomycin-c (fam) combination chemotherapy in the treatment of advanced gastric cancer

2. 5-Fluorouracil, Doxorubicin, and Mitomycin (FAM) Combination Chemotherapy for Advanced Gastric Cancer

3. Treatment of advanced gastric carcinoma with 5-fluorouracil adriamycin, and mitomycin C (FAM)

4. Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study.

5. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277).